Akouos, Inc. AKUS
Day range unavailable
52-week range unavailable
- Market cap
- 491.02M
- Shares out
- 36.95M
- Forward P/E
- -6.78
- Beta
- -0.56
- Analysts
- Hold
- Price target
- 8.50 (-36.0%)
- Earnings date
- Nov 14, 2022
2Y +3.93 (+41.99%)
Key statistics
- Enterprise value
- 351.88M
- PEG ratio
- -0.15
- Price / sales
- 0.00
- Price / book
- 2.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -59.79M
- Total cash
- 169.33M
- Total debt
- 35.37M
- Return on equity
- -42.37%
- Short % of float
- 3.63%
- 50-day average
- 11.93
- 200-day average
- 5.81
Analyst view
Consensus: hold
- Target (low)
- 4.00
- Target (mean)
- 8.50
- Target (high)
- 13.00
- Strong buy1
- Buy1
- Hold3
- Sell0
- Strong sell0
Next earnings
Nov 14, 2022
Expected Nov 14, 2022. Consensus EPS estimate -0.75.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2022 | Sep 1, 2022 | -0.64 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.76 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.73 | — | — | — |
| Mar 29, 2022 | Dec 1, 2021 | -0.66 | — | — | — |
| Nov 12, 2021 | Sep 1, 2021 | -0.63 | — | — | — |
| Aug 12, 2021 | Jun 1, 2021 | -0.48 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2022 | Piper Sandler | down | Overweight | Neutral |
| Oct 19, 2022 | William Blair | down | Outperform | Market Perform |
| Oct 18, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 29, 2022 | William Blair | init | — | Outperform |
| May 18, 2022 | Piper Sandler | main | — | Overweight |
| Apr 27, 2021 | HC Wainwright & Co. | init | — | Buy |
About Akouos, Inc.
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- akouos.com
News
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases 
Lilly and Akouos Announce Expiration of Akouos Tender Offer 
SHAREHOLDER ALERT: Weiss Law Investigates Akouos, Inc. 
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022 
AKOUOS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akouos, Inc. - AKUS 
Why Is Akouos (AKUS) Stock Up 85% Today? 
Why Akouos Stock Is on Fire Today 
Eli Lilly to buy genetic medicine developer Akouos for $487 million 
Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss 
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
Your note
Sign in to keep a note on AKUS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM VENTURES V, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 28, 2020 | 0 |
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 29, 2020 | 0 |
| KEARNY ACQUISITION CORP | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 29, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.41% | 4,582,532 | 60.90M | Sep 29, 2022 |
| NEA Management Company, LLC | 11.64% | 4,298,488 | 57.13M | Sep 29, 2022 |
| 5AM Venture Management, LLC | 11.20% | 4,135,784 | 54.96M | Sep 29, 2022 |
| Federated Hermes, Inc. | 10.80% | 3,988,967 | 53.01M | Sep 29, 2022 |
| VR Adviser, LLC | 7.58% | 2,800,566 | 37.22M | Sep 29, 2022 |
| EcoR1 Capital, LLC | 5.35% | 1,975,984 | 26.26M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Federated Hermes Kaufmann Small Cap Fund | 5.28% | 1,950,000 | 25.92M | Jul 30, 2022 |
| Federated Hermes Kaufmann Fund | 3.74% | 1,380,000 | 18.34M | Jul 30, 2022 |
| Fidelity Select Portfolios - Biotechnology | 2.99% | 1,103,186 | 14.66M | Aug 30, 2022 |
| Fidelity Growth Company Fund | 2.46% | 908,209 | 12.07M | Aug 30, 2022 |
| Vanguard Total Stock Market Index Fund | 1.46% | 538,627 | 7.16M | Jun 29, 2022 |
| BlackRock Health Sciences Trust II | 0.78% | 287,850 | 3.83M | Jun 29, 2022 |